Ankasa Regenerative Therapeutics
Ankasa is developing ART352-L as a novel regenerative medicine. Successful development of ART352-L will enhance the osteogenic properties of patient derived stem cells used in reconstructive surgeries and provide safe and effective enhancement of bone formation in indications for which this is a significant unmet medical need. Ankasa’s lead indication is augmentation of autograft used in spinal fusion for treatment of degenerative changes in intervertebral discs, a highly prevalent chronic, debilitating condition that can severely impact day-to-day functioning. Our preclinical data suggest that treatment of a patient’s autograft with ART352-L will generate significantly more bone without unwanted bone overgrowth, thus reducing the rate of revision surgeries and their attendant complications. This is a direct benefit to the target patient population as well as a direct savings to the healthcare system.
Find locations served, office locations
- Business Type:
- Industry Type:
- Market Focus:
- Nationally (across the country)
Ankasa has raised over $19M from a venture investment syndicate, led by Avalon Ventures and including Heraeus Medical GmbH, Correlation Ventures and Stanford University. We have also been awarded over $6M from The California Institute of Regenerative Medicine (CIRM) in two grants to support pre-clinical research and our Investigational New Drug (IND) submission.